No idea.
I prefer to wait and not guess.
Meanwhile, Gilead continue the search for strategies including control and cure.
GS9620 has recently been (July) proven safe and pharmacologically active, for HIV and HBV. And it has already had success with SHIV. Long winded trials are ongoing.
There is not a huge rush here. MM will be fully up to speed with what is happening across the entire field of cure and/or control programs. Cure strategies are coming along very, very slowly.
Ann: Appointment of International Advisory Board for BIT225, page-107
-
- There are more pages in this discussion • 117 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $17.14M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $5.671K | 298.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 512798 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1050263 | 5 |
View Market Depth
| Last trade - 15.59pm 04/10/2024 (20 minute delay) ? |
| BIT (ASX) Chart |